Minutes - Medication WG 2022-02-15

From Health Level 7 Belgium Wiki
Attendees
  • An Crepel, Digile
  • Annemieke Vergauwe
  • Bart Decuypere
  • Jan Lenie
  • Jean-Michel Polfliet
  • Jens Penny
  • José Costa Teixeira
  • Karlien Erauw
  • Kris Deceunynck
  • Pablo Christiaens
  • Thomas Van Langendonck
  • Tom Henkens
Excused/Not present
  • Anne Nerenhausen
  • Bruno Casneuf
  • Dieter Sauvillers
  • Elhassan Baazizi
  • Hanne Vuegen
  • Jean-Louis Maggetto
  • Jeroen De Wilde
  • Katrien Thorré
  • Lars Vanreppelen
  • Marc Buckens
  • Nick Hermans
  • Nils Devos
  • Richard Francken
  • Thomas Van Langendonck
  • Tom De Backer
  • Walter Bollaert
  • Will van Norel
Agenda
  • presentation and discussion on drug databases
Minutes
  • BCFI, the green booklet used by pharmacists & doctors
  • BCFI was structured in a Repertorium drug tables
  • SAM is a consortium: APB, RIZIV, FOD VG, FAGG to put all drugs in one database
  • VMP, VMP-groups are concepts that were implemented through guidance from BCFI
  • the public SAM viewer was developed by Digile, visualisation in an intuitive manner that has the full SAMv2 content (2 updates a day - not realtime), search is intuitive by brand, substance, code (CTI-extended, CNK), has the business history
  • feedback option is available for the pharma and industry as there are still some data quality issues & inconsistencies with SAM
  • follow-up on raised issues is still difficult
  • CSV experts are available f.e. for overview of VOS-groups to improve easier access to these data that was not open to the public before
  • ISO IDMP gap analysis on SAM V2 has been done
  • ISO IDMP does not present a fixed vocabulary
  • objective is to map SAMv2 to ISO IDMP database, works quite well although there are no identifiers in the 2 systems
  • attributes can be useful for the mapping
  • How can we query with FHIR on SAMv2 ? There is a restful API but not on FHIR
  • what is a VMP group: it is a clinical concept for medicinal products having the same substance, strength, pharmaceutical form and route of administration - seen from the point of view of a clinician (doctor, pharmacist)
  • VMP is a more regulatory concept
  • our WG goal: how to represent medication in a medication scheme - which recommendation to represent the medication ? The current MS is focused on brand name ; VOS-group of substance seems better from a clinical point of view as it includes the route of administration
  • RIZIV wants a different view so both levels will have to be there (packages)
  • The VIDIS project would like to have first artefacts of our WG
  • medication treatment line are being worked on - we need some use cases/examples to make progress - will be ready for next meeting


Action items for next meeting

  • José to work on use cases and add medication view line in view and how it all works at operational level

Agenda items for next meeting

  • medication treatment line examples
  • discuss document listing the concepts to use in the MS.

Next meeting March 1 at 11AM